| Novartis finds Xolair anti-IgE therapy benefits asthma patients | Posted on 06/10/2008 in Pharmacy Supplier News Novartis has found young asthma sufferers may benefit from Xolair anti-IgE therapy.
By targeting IgE, a main cause of symptoms of the allergic form of asthma, a new study showed Xolair (omalizumab) can "significantly" reduce attacks in children aged between six and 11 years old.
Children suffered 31 per cent fewer clinically significant attacks ? or exacerbations ? than patients receiving a placebo over a 24-week period, the study concluded.
Over a one-year period, children administered with Xolair experienced 43 per cent fewer exacerbations.
Professor Bobby Lanier of the University of North Texas Health Science Centre said young asthma sufferers are "particularly vulnerable".
"These data represent an important new approach to treating allergic asthma in children who remain uncontrolled despite their treatment," he said.
The results of the study were revealed at the European Respiratory Society's annual meeting in Berlin. The society was founded in 1990 and has almost 9,000 members in 100 countries.
Other news stories from 06/10/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
